Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an announcement.
Australian Ethical Investment Limited has notified the market that it has ceased to be a substantial shareholder in Australian Clinical Labs Limited, as formalised in a Form 605 lodged with the ASX. The change reduces Australian Ethical’s significant ownership influence in the pathology provider, signalling a shift in its investment position and potentially altering the shareholder landscape for Australian Clinical Labs, although no further operational or strategic implications were disclosed.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the medical diagnostics and pathology testing industry, providing laboratory services to healthcare providers, hospitals, and patients across Australia. The company focuses on clinical testing and related laboratory services that support medical practitioners in diagnosis, treatment, and ongoing patient care.
Average Trading Volume: 607,761
Technical Sentiment Signal: Sell
Current Market Cap: A$507.5M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.